Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding

Journal of Lipid Research

Volumn 54, Issue 12, 2013, Pages 3345-3357

  Gu, Hong Mei ^a   Adijiang, Ayinuer ^a   Mah, Matthew ^a   Zhang, Da Wei ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Epidermal growth factor precursor homology domain A; Ligand binding; Proprotein convertase subtilisin kexin like 9

Indexed keywords

EPIDERMAL GROWTH FACTOR PRECURSOR HOMOLOGY DOMAIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; MUTANT PROTEIN; PROPROTEIN CONVERTASE SUBTILISIN KEXIN LIKE 9; RECOMBINANT EPIDERMAL GROWTH FACTOR PRECURSOR HOMOLOGY DOMAIN A; RECOMBINANT PROTEIN; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; ENDOSOME; HUMAN; MOUSE; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FAMILY; PROTEIN FUNCTION; RECEPTOR BINDING;

EPIDERMAL GROWTH FACTOR PRECURSOR HOMOLOGY DOMAIN A; LIGAND BINDING; PROPROTEIN CONVERTASE SUBTILISIN KEXIN-LIKE 9;

AMINO ACID SEQUENCE; ANIMALS; CERCOPITHECUS AETHIOPS; CONSERVED SEQUENCE; COS CELLS; EPIDERMAL GROWTH FACTOR; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR SEQUENCE DATA; MUTATION; PROPROTEIN CONVERTASES; PROTEIN BINDING; PROTEIN PRECURSORS; PROTEIN STRUCTURE, TERTIARY; PROTEOLYSIS; RECEPTORS, LDL; SERINE ENDOPEPTIDASES;

EID: 84887873435     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M041129     Document Type: Article

References (49)

1. Goldstein, J. L., H. H. Hobbs, and M. S. Brown. 2001. Familial hypercholesterolemia. In The Metabolic and Molecular Bases of Inherited Disease. C. R. Scriver, A. L. Beaudet, W. S. Sly, et al., editors. McGraw-Hill, New York. 2863-2913.
2. Abifadel, M., M. Varret, J. P. Rabes, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34:154-156. (Pubitemid 36666925)
3. Allard, D., S. Amsellem, M. Abifadel, M. Trillard, M. Devillers, G. Luc, M. Krempf, Y. Reznik, J. P. Girardet, A. Fredenrich, et al. 2005. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26:497.
4. Leren, T. P. 2004. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia. Clin. Genet. 65:419-422. (Pubitemid 38659713)
5. Timms, K. M., S. Wagner, M. E. Samuels, K. Forbey, H. Goldfine, S. Jammulapati, M. H. Skolnick, P. N. Hopkins, S. C. Hunt, and D. M. Shattuck. 2004. A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree. Hum. Genet. 114:349-353. (Pubitemid 38324948)
6. Cohen, J. C., and H. H. Hobbs. 2013. Genetics. Simple genetics for a complex disease. Science. 340:689-690.
7. Abifadel, M., J. P. Rabes, M. Devillers, A. Munnich, D. Erlich, C. Junien, M. Varret, and C. Boileau. 2009. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum. Mutat. 30:520-529.
8. Cohen, J., A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, and H. H. Hobbs. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37:161-165.
9. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354:1264-1272.
10. Folsom, A. R., J. M. Peacock, and E. Boerwinkle. 2009. Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease. Atherosclerosis. 202:211-215.
11. Kotowski, I. K., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78:410-422. (Pubitemid 43291224)
12. Hooper, A. J., A. D. Marais, D. M. Tanyanyiwa, and J. R. Burnett. 2007. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 193:445-448. (Pubitemid 47058112)
13. Seidah, N. G., A. M. Khatib, and A. Prat. 2006. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol. Chem. 387:871-877. (Pubitemid 44100233)
14. Zhao, Z., Y. Tuakli-Wosornu, T. A. Lagace, L. Kinch, N. V. Grishin, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79:514-523. (Pubitemid 44384260)
15. Abifadel, M., J. P. Rabes, S. Jambart, G. Halaby, M. H. Gannage-Yared, A. Sarkis, G. Beaino, M. Varret, N. Salem, S. Corbani, et al. 2009. The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene. Hum. Mutat. 30:E682 - E691.
16. Lagace, T. A., D. E. Curtis, R. Garuti, M. C. McNutt, S. W. Park, H. B. Prather, N. N. Anderson, Y. K. Ho, R. E. Hammer, and J. D. Horton. 2006. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J. Clin. Invest. 116:2995-3005. (Pubitemid 44684484)
17. Zhang, D. W., T. A. Lagace, R. Garuti, Z. Zhao, M. McDonald, J. D. Horton, J. C. Cohen, and H. H. Hobbs. 2007. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282:18602-18612. (Pubitemid 47100234)
18. Zhang, D. W., R. Garuti, W. J. Tang, J. C. Cohen, and H. H. Hobbs. 2008. Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 105:13045-13050.
19. Cameron, J., O. L. Holla, T. Ranheim, M. A. Kulseth, K. E. Berge, and T. P. Leren. 2006. Effect of mutations in the PCSK9 gene on the cell surface LDL receptors. Hum. Mol. Genet. 15:1551-1558.
20. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102:2069-2074. (Pubitemid 40262013)
21. Park, S. W., Y. A. Moon, and J. D. Horton. 2004. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. J. Biol. Chem. 279:50630-50638. (Pubitemid 39577880)
22. Grefhorst, A., M. C. McNutt, T. A. Lagace, and J. D. Horton. 2008. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J. Lipid Res. 49:1303-1311.
23. Luo, Y., L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins. 2009. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J. Lipid Res. 50:1581-1588.
24. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. A. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA. 102:5374-5379. (Pubitemid 40530265)
25. Frank-Kamenetsky, M., A. Grefhorst, N. N. Anderson, T. S. Racie, B. Bramlage, A. Akinc, D. Butler, K. Charisse, R. Dorkin, Y. Fan, et al. 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA. 105:11915-11920.
26. McNutt, M. C., T. A. Lagace, and J. D. Horton. 2007. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282:20799-20803. (Pubitemid 47099894)
27. Wang, Y., Y. Huang, H. H. Hobbs, and J. C. Cohen. 2012. Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR. J. Lipid Res. 53:1932-1943.
28. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105:1820-1825. (Pubitemid 351439423)
29. Bottomley, M. J., A. Cirillo, L. Orsatti, L. Ruggeri, T. S. Fisher, J. C. Santoro, R. T. Cummings, R. M. Cubbon, P. Lo Surdo, A. Calzetta, et al. 2009. Structural and biochemical characterization of the wild type PCSK9-EGF (AB) complex and natural familial hypercholesterolemia mutants. J. Biol. Chem. 284:1313-1323.
30. Lo Surdo, P., M. J. Bottomley, A. Calzetta, E. C. Settembre, A. Cirillo, S. Pandit, Y. G. Ni, B. Hubbard, A. Sitlani, and A. Carfi. 2011. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH. EMBO Rep. 12:1300-1305.
31. Gao, X., H. Gu, G. Li, K. A. Rye, and D. W. Zhang. 2012. Identification of an amino acid residue in ATP-binding cassette transport G1 critical for mediating cholesterol efflux. Biochim. Biophys. Acta. 1821:552-559.
32. Gu, H. M., G. Li, X. Gao, L. G. Berthiaume, and D. W. Zhang. 2013. Characterization of palmitoylation of ATP binding cassette transporter G1: effect on protein trafficking and function. Biochim. Biophys. Acta. 1831:1067-1078.
33. Rudenko, G., L. Henry, K. Henderson, K. Ichtchenko, M. S. Brown, J. L. Goldstein, and J. Deisenhofer. 2002. Structure of the LDL receptor extracellular domain at endosomal pH. Science. 298:2353-2358. (Pubitemid 36014201)
34. Van Driel, I. R., C. G. Davis, J. L. Goldstein, and M. S. Brown. 1987. Self-association of the low density lipoprotein receptor mediated by the cytoplasmic domain. J. Biol. Chem. 262:16127-16134.
35. Tveten, K., O. L. Holla, J. Cameron, T. B. Strom, K. E. Berge, J. K. Laerdahl, and T. P. Leren. 2012. Interaction between the ligandbinding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification. Hum. Mol. Genet. 21:1402-1409.
36. Saha, S., J. Boyd, J. M. Werner, V. Knott, P. A. Handford, I. D. Campbell, and A. K. Downing. 2001. Solution structure of the LDL receptor EGF-AB pair: a paradigm for the assembly of tandem calcium binding EGF domains. Structure. 9:451-456. (Pubitemid 32575343)
37. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2007. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32:71-77. (Pubitemid 46199197)
38. Poirier, S., G. Mayer, S. Benjannet, E. Bergeron, J. Marcinkiewicz, N. Nassoury, H. Mayer, J. Nimpf, A. Prat, and N. G. Seidah. 2008. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283:2363-2372.
39. Lakoski, S. G., T. A. Lagace, J. C. Cohen, J. D. Horton, and H. H. Hobbs. 2009. Genetic and metabolic determinants of plasma PCSK9 levels. J. Clin. Endocrinol. Metab. 94:2537-2543.
40. Yamamoto, T., C. Lu, and R. O. Ryan. 2011. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J. Biol. Chem. 286:5464-5470.
41. Beglova, N., H. Jeon, C. Fisher, and S. C. Blacklow. 2004. Structural features of the low-density lipoprotein receptor facilitating ligand binding and release. Biochem. Soc. Trans. 32:721-723. (Pubitemid 39524362)
42. Beglova, N., H. Jeon, C. Fisher, and S. C. Blacklow. 2004. Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor. Mol. Cell. 16:281-292. (Pubitemid 39388842)
43. Shan, L., L. Pang, R. Zhang, N. J. Murgolo, H. Lan, and J. A. Hedrick. 2008. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem. Biophys. Res. Commun. 375:69-73.
44. Trommsdorff, M., M. Gotthardt, T. Hiesberger, J. Shelton, W. Stockinger, J. Nimpf, R. E. Hammer, J. A. Richardson, and J. Herz. 1999. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell. 97:689-701. (Pubitemid 29278044)
45. Roubtsova, A., M. N. Munkonda, Z. Awan, J. Marcinkiewicz, A. Chamberland, C. Lazure, K. Cianflone, N. G. Seidah, and A. Prat. 2011. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31:785-791.
46. Mayne, J., T. Dewpura, A. Raymond, M. Cousins, A. Chaplin, K. A. Lahey, S. A. Lahaye, M. Mbikay, T. C. Ooi, and M. Chretien. 2008. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 7:22.
47. Careskey, H. E., R. A. Davis, W. E. Alborn, J. S. Troutt, G. Cao, and R. J. Konrad. 2008. Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J. Lipid Res. 49:394-398. (Pubitemid 351213624)
48. McNutt, M. C., H. J. Kwon, C. Chen, J. R. Chen, J. D. Horton, and T. A. Lagace. 2009. Antagonism of secreted PCSK9 increases low-density lipoprotein receptor expression in HEPG2 cells. J. Biol. Chem. 284:10561-10570.
49. Zhang, Y., L. Zhou, M. Kong-Beltran, W. Li, P. Moran, J. Wang, C. Quan, J. Tom, G. Kolumam, J. M. Elliott, et al. 2012. Calcium-Independent Inhibition of PCSK9 by Affinity-Improved Variants of the LDL Receptor EGF (A) Domain. J. Mol. Biol. 422:685-696.